Alkali Metal Or Alkaline Earth Containing Patents (Class 424/722)
-
Patent number: 12223643Abstract: Described are platforms, systems, and methods for screening patients. In one aspect, a computer-implemented method comprises: receiving, from a cellular imaging device, image data comprising calcium kinetic features of neuronal cultures derived from a patient; processing the image data through a machine-learning model to determine a diagnosis for the patient based on the calcium kinetic features, the machine-learning model trained using neuronal calcium data; and providing the diagnosis a user interface.Type: GrantFiled: May 29, 2020Date of Patent: February 11, 2025Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTEInventors: Cameron Pernia, Heather Tolcher, Evan Y. Snyder
-
Patent number: 12114683Abstract: Provided is a gelling composition capable of keeping a gel state in a food even when the food heated at 75° C. is cooled to around 45° C. at which the food can be eaten in a warm state. Specifically provided is a gelling composition comprising methyl cellulose, a 2.0% by weight aqueous solution of which has a storage modulus G? (75° C.) at 75° C. of 3,000 to 5,500 Pa, the 2.0% by weight aqueous solution of which has a return temperature storage modulus G? (75 to 45° C.) of 2,000 to 3,600 Pa when the temperature of the aqueous solution is returned from 75° C. to 45° C., and a 2.0% by weight aqueous solution of which has a viscosity at 20° C. of 3,000 to 10,000 mPa·s; a low temperature gelling agent; and a solvent. A food comprising the gelling composition is also provided.Type: GrantFiled: May 25, 2017Date of Patent: October 15, 2024Assignee: SHIN-ETSU CHEMICAL CO., LTD.Inventors: Atsushi Yamamoto, Shingo Niinobe, Akira Kitamura
-
Patent number: 12083080Abstract: Disclosed are methods of treating a patient having Major Depressive Disorder (MDD) or Treatment Resistant Depression (TRD). The methods include administering to the patient a therapeutically effective amount of bupropion hydrobromide in extended-release form. The methods are more therapeutically effective in treating MDD or TRD than administration of an equivalent plasma dose of bupropion hydrochloride in extended-release form. In addition or alternatively, the therapeutically effective amount of bupropion hydrobromide reduces the incidence of one or more adverse events (anxiety, agitation and/or insomnia), when compared to the administration of the equivalent plasma dose of bupropion hydrochloride in extended-release form.Type: GrantFiled: January 4, 2024Date of Patent: September 10, 2024Inventors: Richard Louis Price, Maxwell Zachary Price
-
Patent number: 11877896Abstract: The present invention teaches minimally invasive apparatuses and methods for stabilizing and/or guiding medical instruments used in a variety of medical procedures, including (a) introducing one or more substances into a subject's body, (b) removing one or more substances from a subject's body, (c) manipulating a region of a subject's body, or (d) combinations thereof. Among the many advantages of the inventive apparatuses are their simplicity and adaptability to attach to a variety of retractors.Type: GrantFiled: November 15, 2019Date of Patent: January 23, 2024Assignee: Cedars-Sinai Medical CenterInventors: Pablo Avalos, Doniel Drazin, Clive Svendsen
-
Patent number: 11844786Abstract: The invention relates to pharmaceutical compositions containing both (+)-?-dihydrotetrabenazine and (?)-?-dihydrotetrabenazine and their therapeutic uses, for example in the treatment of movement disorders, such as Tourette's syndrome.Type: GrantFiled: March 29, 2018Date of Patent: December 19, 2023Assignee: ADEPTIO PHARMACEUTICALS LIMITEDInventors: Andrew John Duffield, Anant Pandya
-
Patent number: 11833157Abstract: Embodiments of the invention are directed to formulations that provide a solution to the problem of small molecule (e.g., diazepam) precipitation at the injection site when administered as a highly-concentrated formulation. In certain aspects the formulations include at least one surfactant in a non-aqueous formulation, which prevents small molecule precipitation and improves the bioavailability of the drug by enhancing absorption into the systemic circulation.Type: GrantFiled: May 13, 2021Date of Patent: December 5, 2023Assignee: Xeris Pharmaceuticals, Inc.Inventors: Steven J. Prestrelski, Michael A. Sandoval, Brian R. Sloat
-
Patent number: 11771662Abstract: Provided herein are treatments for reducing pain in dogs. The treatments generally comprise a combination of an opioid compound, such as methadone, and an azole compound, such as fluconazole. The treatments may further comprise an opioid abuse deterrent that advantageously inhibits opioid effects in humans while maintaining desirable analgesic effects in dogs. Additionally, the treatments provided herein avoid the undesirable side effects of prior art opioid treatments for dogs. The treatments may be administered as separate doses or in a single formulation product for improved compliance. The treatments have wide use potential in dogs from perioperative patients to inpatients and outpatients and may be used, for example, for sedation in minor procedures, analgesia, and decreasing temperature in canine patients.Type: GrantFiled: September 5, 2018Date of Patent: October 3, 2023Assignee: Kansas State University Research FoundationInventors: Stanley KuKanich, Katherine KuKanich, Charles W. Locuson, David Rankin
-
Patent number: 11679090Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.Type: GrantFiled: November 30, 2020Date of Patent: June 20, 2023Assignee: Navitor Pharmaceuticals, Inc.Inventors: Eddine Saiah, George Vlasuk
-
Patent number: 11638831Abstract: The present invention relates to treatment of a psychiatric condition, for example resistant depression (RD), bipolar disorder (either threshold or sub-threshold) and/or major depressive disorder via application of repetitive transcranial magnetic stimulation with a drug treatment, in particular application of repetitive transcranial magnetic stimulation with treatment to modulate the activity of the neurones and induce neuroplasticity and the use of Thyroid hormone treatment to increase quantity or activity of thyroid hormones, for example for treatment of thyroid dysfunction. Patients may be selected for treatment by testing for the presence of normal thyroid function.Type: GrantFiled: December 14, 2018Date of Patent: May 2, 2023Assignee: THE LONDON PSYCHIATRY CENTREInventor: Antonios Zamar
-
Patent number: 11622951Abstract: The invention provides compositions and methods for preserving, restoring, or enhancing vision of a subject by administering compositions to an injured or diseased eye.Type: GrantFiled: August 13, 2020Date of Patent: April 11, 2023Assignee: The Schepens Eye Research Institute, Inc.Inventors: Dong Feng Chen, Kin-Sang Cho
-
Patent number: 11612642Abstract: The present disclosure generally relates to methods and formulations for treating central nervous system (CNS) disorders. The present disclosure involves intranasal delivery of at least one antioxidant compound, allowing for effective treatment of a central nervous system disorder such as traumatic brain injury or stroke.Type: GrantFiled: April 27, 2020Date of Patent: March 28, 2023Assignee: Beyond Barriers Therapeutics, Inc.Inventors: Ryan Kole, John Marshall, Meriel Owen
-
Patent number: 11559472Abstract: A skin treatment product and method includes steps of detoxifying cleansing, tightening, and moisturizing skin, by applying bentonite paste, followed by a skin moisturizer, to provide improved skin health and appearance. A single packaging contains bentonite paste and the skin moisturizer. The bentonite paste may be applied in a first step to extract oils, toxins, bacteria and other materials from the skin. After the bentonite paste dries and is removed, the moisturizer is applied to the skin, preferably a vitamin and/or mineral infused moisturizer. In one embodiment, the skin moisturizer is in the form of a skin mask. Following moisturizing the skin, a third step may be to nourish the skin. The skin treatment may be applied to facial skin, feet, hands, or any skin surface.Type: GrantFiled: July 22, 2020Date of Patent: January 24, 2023Inventors: Terry Suzuki, Lisa Suzuki, Chelsea Suzuki, Benjamin LaBelle
-
Patent number: 11446350Abstract: The present invention relates to processes and composition meant for delaying ageing process in a subject comprising of palm fruit juice whole or its fractions, alone or in combination with other components in the form of a composition. Palm Fruit Juice alone or in combination with other additives can be administered preferably orally in pharmaceutically acceptable dosage forms.Type: GrantFiled: March 8, 2019Date of Patent: September 20, 2022Assignee: MALAYSIAN PALM OIL BOARDInventors: Soon Sen Leow, Ravigadevi Sambanthamurthi, Kenneth C. Hayes
-
Patent number: 11149036Abstract: The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.Type: GrantFiled: June 22, 2018Date of Patent: October 19, 2021Assignees: MSD R&D (China) Co., Ltd., Merck Sharp & Dohme Corp.Inventors: John J. Acton, III, Jianming Bao, Qiaolin Deng, Melissa Egbertson, Ronald Ferguson, II, Xiaolei Gao, Scott Timothy Harrison, Sandra L. Knowles, Chunsing Li, Michael Man-Chu Lo, Robert D. Mazzola, Jr., Zhaoyang Meng, Meng Na, Michael T. Rudd, Oleg Selyutin, David M. Tellers, Ling Tong, Fengqi Zhang
-
Patent number: 10799492Abstract: The present invention provides novel deuterated analogs of Pridopidine, i.e. 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine. Pridopidine is a drug substance currently in clinical development for the treatment of Huntington's disease. In other aspects the invention relates to pharmaceutical compositions comprising a deuterated analog of Pridopidine of the invention, and to therapeutic applications of these analogs.Type: GrantFiled: September 17, 2018Date of Patent: October 13, 2020Assignee: PRILENIA NEUROTHERAPEUTICS LTD.Inventor: Clas Sonesson
-
Patent number: 10780070Abstract: The invention provides compositions and methods for preserving, restoring, or enhancing vision of a subject by administering compositions to an injured or diseased eye.Type: GrantFiled: October 20, 2014Date of Patent: September 22, 2020Assignee: The Schepens Eye Research Institute, Inc.Inventors: Dong Feng Chen, Kin-Sang Cho
-
Patent number: 10772875Abstract: The present invention relates to agents enhancing HuR/ELAV levels for use in the treatment of BRAF-mutated cancers and uses thereof. In particular, the invention relates to the use of agents enhancing HuR/ELAV levels in combination with BRAF inhibitors for the treatment of BRAF-mutated cancers, in particular melanoma and to methods for identifying agents useful for potentiating the effects of BRAF inhibitors, when used in combination.Type: GrantFiled: March 14, 2018Date of Patent: September 15, 2020Assignee: LES HOPITAUX UNIVERSITAIRES DE GENEVEInventor: Rastine Mérat
-
Patent number: 10590127Abstract: The present application provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R1-R4 are defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2X3 or P2X2/3 receptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient. In another embodiment, these compounds are useful for treating respiratory dysfunction in patients by administering one or more of the compounds to a patient.Type: GrantFiled: January 22, 2018Date of Patent: March 17, 2020Assignee: Asana BioSciences, LLCInventors: Scott K. Thompson, Aranapakam Venkatesan, Tony Priestley, Mrinal Kundu, Ashis Saha
-
Patent number: 10512506Abstract: The present invention teaches minimally invasive apparatuses and methods for stabilizing and/or guiding medical instruments used in a variety of medical procedures, including (a) introducing one or more substances into a subject's body, (b) removing one or more substances from a subject's body, (c) manipulating a region of a subject's body, or (d) combinations thereof. Among the many advantages of the inventive apparatuses are their simplicity and adaptability to attach to a variety of retractors.Type: GrantFiled: April 30, 2014Date of Patent: December 24, 2019Assignee: Cedars-Sinai Medical CenterInventors: Pablo Avalos, Doniel Drazin, Clive Svendsen
-
Patent number: 10400198Abstract: A method of sanitizing a surface is described that includes: (a) providing a pH control composition that includes at least one pH control agent (such as sodium bisulfate); (b) contacting a first feed aqueous stream with the pH control composition, thereby forming a first treated aqueous stream; (c) combining at least a portion of the first treated aqueous stream with a feed sanitizing aqueous stream that includes free available halogen, thereby forming a treated sanitizing aqueous stream that includes free available halogen (such as free available chlorine). The surface sanitizing method further includes, (d) elevating the temperature of the treated sanitizing aqueous stream, thereby forming a heated treated sanitizing aqueous stream having an elevated temperature that includes free available halogen. The heated treated sanitizing aqueous stream is applied to a surface to be sanitized (such as a poultry carcass surface).Type: GrantFiled: August 17, 2017Date of Patent: September 3, 2019Assignees: EAGLE US 2 LLC, SOUTHEASTERN SYSTEMS, INC.Inventors: Richard H. Ferguson, Christopher M. Kareis, Walter Neal Stanford, Michael Eugene Allen
-
Patent number: 10294457Abstract: The present invention relates to directed differentiation and maturation of hepatocyte-like cells. In particular, the present invention relates to exposure of hepatocyte-like cells to an activator of a retinoic acid responsive receptor, such as retinoic acid (RA), optionally in combination with an inhibitor of GSK-3 (Glycogen synthase kinase 3) or activator of Wnt signalling and/or with the overlay of the cells with one or more components characteristic of the mammalian extracellular matrix (matrix overlay). The present invention also relates to exposure of hepatocyte-like cells to an activator of a retinoic acid responsive receptor, such as retinoic acid (RA), optionally in combination with an inhibitor of a cycline dependent kinase (CDK) and/or with the overlay of the cells with one or more components characteristic of the mammalian extracellular matrix (matrix overlay).Type: GrantFiled: November 28, 2013Date of Patent: May 21, 2019Assignee: Takara Bio Europe ABInventors: Barbara Küppers-Munther, Josefina Edsbagge
-
Patent number: 10098909Abstract: The invention relates to a pharmaceutical composition comprising an ionic co-crystal (ICC) of lithium with salicylic acid and 1-proline (LISPRO). The pharmaceutical composition can further comprise an anti-inflammatory agent, for example, salicylic acid. An embodiment of the invention provides a method for treating Fragile X Syndrome (FXS) in a subject by administering to the subject a composition comprising a pharmaceutically effective amount of LISPRO.Type: GrantFiled: February 6, 2017Date of Patent: October 16, 2018Assignee: UNIVERSITY OF SOUTH FLORIDAInventors: Jun Tan, Roland Douglas Shytle
-
Patent number: 9908879Abstract: The present application provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R1-R4 are defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2X3 or P2X2/3 receptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient. In another embodiment, these compounds are useful for treating respiratory dysfunction in patients by administering one or more of the compounds to a patient.Type: GrantFiled: June 16, 2016Date of Patent: March 6, 2018Assignee: Asana Biosciences, LLCInventors: Scott K. Thompson, Aranapakam Venkatesan, Tony Priestley, Mrinal Kundu, Ashis Saha
-
Patent number: 9687440Abstract: Compositions comprising at least one ingredient that stimulates, enhances, or increases CGRP expression, and a physiologically- or cosmetically-acceptable vehicle. The ingredient may be a compound, natural ingredient, such as a plant or fungus, derivatives, analogs, mimetics, synthetics and the like that stimulates CGRP expression. The CGRP plant includes plants, plant materials, plant extracts, synthetics, or combinations thereof that stimulate CGRP expression. The disclosure is also directed to methods of using the CGRP compositions for decreasing, reducing, or inhibiting fine lines or wrinkled skin.Type: GrantFiled: March 26, 2015Date of Patent: June 27, 2017Assignee: Avon Products, IncInventors: John W. Lyga, Laurence Dryer
-
Patent number: 9545446Abstract: This invention provides a method of colonic cleansing.Type: GrantFiled: February 25, 2014Date of Patent: January 17, 2017Assignee: SYNERGY PHARMACEUTICALS, INC.Inventors: Dennis Riff, Gary S. Jacob, Kunwar Shailubhai, Patrick H. Griffin
-
Patent number: 9186318Abstract: Provided in the present invention is a quinolyl-containing hydroxamic acid compound as shown in formula (I), at the same time also disclosed is the preparation method of the compound and the use thereof, and a pharmaceutical composition containing the quinolyl-containing hydroxamic acid compound. Such compounds are inhibitors of protein kinases and/or histone deacetylases, and can be used in the treatment of diseases caused by the abnormal activity of protein kinases and/or histone deacetylases, for example, tumors, etc.Type: GrantFiled: September 27, 2011Date of Patent: November 17, 2015Assignee: Beijing Konruns Pharmaceutical Co., LtdInventors: Ziwei Yun, Hongtao Wang
-
Patent number: 9044418Abstract: Treating mental illness by administering synthetic isotope-modified lithium compounds: (i) with the lithium-6 isotope making up at least 95% of the total number of lithium atoms in the compound to treat depression and other mental conditions with reduced alertness levels, (ii) with the lithium-7 isotope making up at least 95% of the total number of lithium atoms in the compound to treat mania and bipolar disorder and other mental illnesses which respond to lithium compounds with natural isotope abundance levels, (iii) with the lithium-6 isotope ranging from 10% to 95% of the total number of lithium atoms in the compound individually tailored to treat patients with a broad variety of mental disorders, including those in (i) and (ii) above.Type: GrantFiled: October 10, 2014Date of Patent: June 2, 2015Inventor: Matthew P. A. Fisher
-
Patent number: 9034394Abstract: Provided is a method of preparing a red clay processed material using red clay and sodium hydroxide and a red clay processed material having anti-corrosive and virus disinfecting activity. Also, a method of preparing alkali ionized water having excellent anti-bacterial, virus disinfecting and anti-corrosive activity using the red clay processed material, alkali ionized water using the same, and a functional product including the same are provided. The red clay processed material and the method of preparing alkali ionized water using the same can reduce the reaction temperature and reaction time compared to a conventional process, thereby significantly reducing the production cost.Type: GrantFiled: February 3, 2010Date of Patent: May 19, 2015Assignee: Dongguk University Industry-Academic Cooperation FoundationInventors: Jung-Keug Park, Moon Young Yoon
-
Publication number: 20150118180Abstract: Formulations containing reactive oxygen species (ROS), processes for making these formulations, and methods of using these formulations are described. The formulations can include gels or hydrogels that contain at least one reactive oxygen species (ROS). The formulations can include a composition containing a reduced species (RS) and a reactive oxygen species (ROS). The formulations can also contain a rheology modifier and can include gels or hydrogels. Methods of preparing the formulations can include preparing a composition. Compositions can be prepared by providing water, purifying the water to produce ultra-pure water, combining sodium chloride to the ultra-pure water to create salinated water, and electrolyzing the salinated water at a temperature between about 4.5 to about 5.8° C.Type: ApplicationFiled: October 24, 2014Publication date: April 30, 2015Applicant: REOXCYN DISCOVERIES GROUP, INC.Inventor: Andres Hoover
-
Publication number: 20150118327Abstract: Compounds, e.g., of formula (I) and (Ia), pharmaceutical compositions comprising the compounds and methods of using the compounds and pharmaceutical compositions for treating pain disorders, e.g., disorders associated with cephalic pain, are provided.Type: ApplicationFiled: October 9, 2014Publication date: April 30, 2015Inventor: Richard Andrew Sewell
-
Patent number: 9017735Abstract: Disclosed herein are compositions and methods for treating a psychiatric disorder or symptoms thereof in a patient. The compositions comprise a compound that modulates KCNQ (Kv7) potassium channel activity and the methods include administering an effective amount of the compound that modulates KCNQ (Kv7) potassium channel activity.Type: GrantFiled: June 3, 2010Date of Patent: April 28, 2015Assignee: Marquette UniversityInventor: Mohammadhossein Behnam Ghasemzadeh
-
Patent number: 9011931Abstract: A composition used to facilitate healing of cold sores, fever blisters and canker sore that includes potassium, rubidium, zinc, calcium and sodium is provided. This composition is compounded into a polyethylene glycol ointment containing allantoin (0.5 to 2 percent) and camphor (0.1 to 3 percent) and/or menthol (0.1 to 1 percent). In another embodiment, a method to treat cold sores, fever blisters and canker sores is provided by applying an effective amount of this composition to cold sores, fever blisters and canker sores of a subject in need of treatment thereof.Type: GrantFiled: February 18, 2014Date of Patent: April 21, 2015Inventors: Libby Robinson, Mikel Hays
-
Publication number: 20150104528Abstract: Treating mental illness by administering synthetic isotope-modified lithium compounds: (i) with the lithium-6 isotope making up at least 95% of the total number of lithium atoms in the compound to treat depression and other mental conditions with reduced alertness levels, (ii) with the lithium-7 isotope making up at least 95% of the total number of lithium atoms in the compound to treat mania and bipolar disorder and other mental illnesses which respond to lithium compounds with natural isotope abundance levels, (iii) with the lithium-6 isotope ranging from 10% to 95% of the total number of lithium atoms in the compound individually tailored to treat patients with a broad variety of mental disorders, including those in (i) and (ii) aboveType: ApplicationFiled: October 10, 2014Publication date: April 16, 2015Inventor: Matthew P. A. Fisher
-
Publication number: 20150099014Abstract: The invention provides a biocidal and antifouling composition comprising hydrobromic acid, urea and sodium hypo-chloride from highly concentrated precursors and a process for manufacturing the composition.Type: ApplicationFiled: March 6, 2013Publication date: April 9, 2015Inventors: Shlomo Antebi, David Feldman, Chen Zolkov
-
Publication number: 20150099015Abstract: Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.Type: ApplicationFiled: November 24, 2014Publication date: April 9, 2015Inventor: Guochuan Emil TSAI
-
Patent number: 8999297Abstract: A generally non-acidic hemostatic agent, having a relatively neutral pH comprising a magnesium compound, such as a magnesium chloride, a magnesium sulfate and/or a magnesium acetate based compound. The resultant agent is generally less caustic than previous agents, when using a similar amount of active material.Type: GrantFiled: July 13, 2009Date of Patent: April 7, 2015Assignee: Inter-Med, Inc.Inventors: Gary J. Pond, John Baeten
-
Patent number: 8968797Abstract: Methods of preparing bioactive composites are described. Also described are methods of molding such composites. Shaped bodies comprising bioactive composites are further described.Type: GrantFiled: September 25, 2007Date of Patent: March 3, 2015Assignee: Orthovita, Inc.Inventors: James P. Murphy, Erik M. Erbe, Charanpreet S. Bagga, Marissa M. Darmoc
-
Publication number: 20150056308Abstract: Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).Type: ApplicationFiled: June 17, 2014Publication date: February 26, 2015Inventors: Dennis S. Charney, Sanjay J. Mathew, Husseini K. Manji, Carlos A. Zarate, John H. Krystal
-
Publication number: 20150050294Abstract: The present invention relates to a method for diagnosing neuroendocrine cancers via detecting the presence of N-methyl D-asparate-associated (NMDA) glutamate receptors type 1 and/or type 2. Methods for preventing and treating neuroendocrine cancers are also disclosed.Type: ApplicationFiled: October 27, 2014Publication date: February 19, 2015Inventor: William G. North
-
Patent number: 8956667Abstract: Methods of preparing compositions for preferential distribution of active agents to injury sites are provided. The compositions may comprise a polymer with hydrophilic properties and one or more active agents, such as compounds comprising hydrophilic metal ions. Because the delivery ligand and the active agent are specifically selected so the interactions between them are mainly of an ionic nature. Methods of identifying suitable components for such compositions are also disclosed.Type: GrantFiled: March 25, 2010Date of Patent: February 17, 2015Assignee: Warsaw Orthopedic, Inc.Inventors: Josee Roy, Victor Kelley, Roger E. Harrington
-
Patent number: 8957027Abstract: The present invention relates to deacetylase inhibitor (e.g., histone deacetylase inhibitor) therapies and demonstrates that individuals with low electrolyte levels may have increased susceptibility to certain unwanted side effects such as cardiac side effects. In some embodiments, the invention provides methods of administering DAC or DAC inhibitor therapy that includes electrolyte supplementation.Type: GrantFiled: June 7, 2007Date of Patent: February 17, 2015Assignee: Celgene CorporationInventors: William McCulloch, Richard L. Piekarz, Susan E. Bates
-
Publication number: 20150044261Abstract: The presently described technology provides a novel class of prodrugs of quetiapine that can be synthesized by chemically conjugating fatty acids to quetiapine. Pharmaceutical compositions and methods of synthesizing conjugates of the present technology are also provided. Methods of treating patients with the compositions of the present technology are also provided.Type: ApplicationFiled: October 28, 2014Publication date: February 12, 2015Inventors: Travis Mickle, Sven Guenther, Sanjib Bera
-
Publication number: 20150037380Abstract: A skin smoothing film made from a skin smoothing composition that comprises sodium silicate, polyvalent silicate and water. Moreover, the film may be made from a composition that has a contraction value of from about 30% to about 160%. The film thickness is from about 5 microns to about 50 microns, preferably from about 10 microns to about 40 microns, when applied. The standard deviation of the film over the area covered is less than about 30, preferably less than about 25.Type: ApplicationFiled: July 15, 2014Publication date: February 5, 2015Inventors: Amanda Leigh NEWMAN, Nancy Lorincz LEPPLA, Laurie Ellen BREYFOGLE, Gordon Gerald GUAY, David Edward WILSON, Joseph Michael ZUKOWSKI
-
Patent number: 8945607Abstract: A method of managing dehydration in an animal includes administering a first electrolyte solution having an SID range at or below 25 mEq/l. After administering the first electrolyte solution, the animal's health condition is observed to determine the effect of the first solution. If the animal's health condition has not sufficiently improved, a second solution comprising the first electrolyte solution supplemented with a second electrolyte supplement is administered to the animal wherein the second electrolyte supplement raises the SID of the second solution to at least 50 mEq/l.Type: GrantFiled: February 10, 2014Date of Patent: February 3, 2015Assignee: Purina Animal Nutrition LLCInventors: Thomas Johnson, Bill L. Miller
-
Publication number: 20150030704Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.Type: ApplicationFiled: August 21, 2012Publication date: January 29, 2015Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: William Farnaby, Charlotte Fieldhouse, Katherine Hazel, Catrina Kerr, Natasha Kinsella, David Livermore, Kevin Merchant, David Miller
-
Publication number: 20150024070Abstract: A treatment and prevention formulation for canker sores of the oral cavity including an aqueous alkaline solution having at least three B vitamins, zinc and iron mixed therein and administered to a target area by a spray container. The vitamins are B6, B9 and B12, but may include other vitamins as well. The formulation is all-natural, non-toxic and completely ingestible, so it may be used almost anywhere and at almost any time and can be swallowed after use.Type: ApplicationFiled: July 18, 2013Publication date: January 22, 2015Inventors: Plato Chun-Chih Lee, Arthur Joseph Dietrich
-
Publication number: 20150024071Abstract: The present invention relates to 4-pyridinone compounds which are inhibitors of catechol O-methyltransferase (COMT), and are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which COMT enzyme is involved. The present invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which COMT is involved.Type: ApplicationFiled: September 30, 2014Publication date: January 22, 2015Applicant: Merck Sharp & Dohme Corp.Inventors: Scott Wolkenberg, Scott T. Harrison, James C. Barrow, Zhijan Zhao, Jeffrey Melamed, Nathan R. Kett, Amy Zartman
-
Publication number: 20150017266Abstract: Compositions and methods for relieving symptoms of rheumatoid arthritis (RA) and related illnesses are disclosed. It appears that the primary cause of RA is a sensitivity or hypersensitivity to potassium and/or vitamin C, or too much potassium and/or vitamin C in the diet. The effects of potassium and vitamin C on the body must be modified to relieve the symptoms of RA and related illnesses. It appears that magnesium does not cause the inflammation, but appears that it exacerbates the problem. It appears that calcium and vitamin D intake, possibly in combination with the reduced or no intake of potassium and/or vitamin C, may also help to relieve the symptoms of RA and related illnesses.Type: ApplicationFiled: October 2, 2014Publication date: January 15, 2015Inventor: LUCILLE TOWNSEND
-
Publication number: 20150017260Abstract: A nutritional supplement composition for treating nutritional deficiencies caused by a medical condition in subjects is disclosed. The present application further discloses a method of using a nutritional supplements composition for treating a subject with complications resulting from sickle cell anemia. The method comprises administering to a subject an effective amount of the nutritional supplement.Type: ApplicationFiled: July 28, 2014Publication date: January 15, 2015Inventors: Jacqueline M. Hibbert, Jonathan K. Stiles, Kayellen Umeakunne, Hyacinth I. Hyacinth
-
Publication number: 20150010663Abstract: The present disclosure consists of therapeutically-active compositions that combine strontium with at least one additional molecules that increase the overall therapeutic potency of the combination beyond the potency of any of the separate constituents. Specifically, the combinations described herein perform two important functions; (1) they increase the ability of topically-applied strontium to inhibit both acute sensory irritation (e.g., pruritus and pain), redness, swelling and inflammation (collectively defined for purposes of this description, “irritation”) and the chronic irritation that is characteristic of and contributes to the development and maintenance of painful or pruritic neuropathic conditions; and (2) they decrease the strontium activated pathways that are known to enhance the development and maintenance of pain, pruritis and neuropathic conditions.Type: ApplicationFiled: September 22, 2014Publication date: January 8, 2015Applicant: Cosmederm Bioscience, Inc.Inventor: Gary S. HAHN